[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356178-105":59,"doc-detail-356178-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","oral-retinol-alone-or-combined-with-medical-photoprotection-in-patients-with-actinic-keratosis-a-randomized-open-label-prospective-multicentric-study","Oral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis - A Randomized, Open-Label, Prospective, Multicentric Study","","Actinic keratosis (AK) is a chronic ultraviolet-induced condition with potential progression to squamous cell carcinoma. This multicenter, prospective, randomized, open-label trial assessed oral retinol given alone or combined with broad-spectrum medical photoprotection in patients with mild-to-moderate AK. Treatment lasted 6 months with 3 months follow-up, using AKASI change as the primary endpoint and evaluating clinical efficacy, lesion clearance, tolerability, and imaging findings.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oral-retinol-alone-or-combined-with-medical-photoprotection-in-patients-with-actinic-keratosis-a-randomized-open-label-prospective-multicentric-study/356178/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oral-retinol-alone-or-combined-with-medical-photoprotection-in-patients-with-actinic-keratosis-a-randomized-open-label-prospective-multicentric-study/356178.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary endpoint of the study?","Question",{"text":113,"@type":114},"The primary endpoint was the change in the Actinic Keratosis Area and Severity Index (AKASI).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the patients assigned to treatment groups?",{"text":118,"@type":114},"Patients were randomized to oral retinol 50,000 IU/day (group A), oral retinol plus medical photoprotection (group B), or standard photoprotection recommendations (group C).",{"name":120,"@type":111,"acceptedAnswer":121},"What did the results show about oral retinol combined with photoprotection?",{"text":122,"@type":114},"Oral retinol combined with medical photoprotection produced earlier and greater improvements than oral retinol alone or standard photoprotection, with significant reductions observed across multiple time points in group B.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356178,1790495028,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Dermatol Ther (Heidelb) (2026) 16:4705–4718 [https://doi.org/10.1007/s13555-026-01881-0](https://doi.org/10.1007/s13555-026-01881-0)  \nORIGINAL RESEARCH  \nOral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis:  \nA Randomized, Open‑Label, Prospective, Multicentric Study  \nMarco Ardigò · Martina Burlando · Elena Campione · Gianluca Nazzaro · Giulio Foggi · Francesca Colombo · Stefano Alfano · Massimo Milani · Angelo V. Marzano  \nReceived: June 5, 2026 / Accepted: July 24, 2026 / Published online: August 13, 2026 © The Author(s) 2026  \nABSTRACT  \nIntroduction: Actinic keratosis (AK) is a chronic ultraviolet-induced condition with potential progression to squamous cell carcinoma. This study assessed the efficacy and tolerability of oral retinol, alone or combined with broad-spectrum medical photoprotection  \nM. Ardigò · G. Foggi  \nDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy  \nM. Ardigò · G. Foggi  \nDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy  \nM. Burlando  \nDermatology Unit, IRCCS San Martino University Hospital, Genoa, Italy  \nE. Campione  \nDermatological Clinic, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy  \nG. Nazzaro · A. V. Marzano  \nDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy  \nG. Nazzaro · A. V. Marzano  \nDepartment of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milan, Italy  \nF. Colombo (*) · S. Alfano · M. Milani  \nMedical Department, Cantabria Labs Difa Cooper, Caronno Pertusella, VA, Italy  \ne-mail: [francesca.colombo@difacooper.com](francesca.colombo@difacooper.com)  \ncontaining piroxicam, in patients with mild-tomoderate AK.  \nMethods: In this multicenter, prospective, randomized, open-label study, 117 patients with up to six AK lesions were assigned to oral retinol 50,000 international units (IU)/day (group A), oral retinol plus medical photoprotection (group B), or standard photoprotection recommendations (group C) . Treatment lasted 6 months, followed by 3 months of follow-up. Assessments were performed at baseline and at months 3, 6, and 9. The primary endpoint was change in Actinic Keratosis Area and Severity Index (AKASI) . Secondary outcomes included global clinical efficacy, lesion clearance, tolerability, and exploratory line-field confocal optical coherence tomography findings.  \nResults: All 117 patients were included in the intention-to-treat analysis, and 99 in the perprotocol analysis. AKASI scores decreased significantly in group A at month 6 by − 19.3%(mean difference (MD) 0.61, 95% confidence interval (CI) 0.11–1.11; p\u003C 0.05) and at month 9 by−22.5%(MD 0.71, 95% CI 0.18–1.25; p\u003C 0.01) . In group B, significant reductions were observed at all time points (T3: − 24.1%; MD 0.90, 95% CI 0.42–1.39; p \u003C 0.0001; T6: − 34.9%; MD 1.31, 95% CI 0.86–1.76; p \u003C 0.0001; T9: − 38.8%; MD 1.45, 95% CI 0.95–1.95; p \u003C 0.0001) . No significant changes occurred in group C. Reductions were earlier and greater with the combined strategy. Global clinical efficacy was rated good or  \nvery good in 69% of patients in group A and 88% in group B, while lesion clearance rates were 56% and 82%, respectively. Tolerability was generally good, and no treatment-related adverse events were formally recorded. In the imaging substudy, significant reductions in epidermal and stratum corneum thickness occurred only in group B.  \nConclusions: Oral retinol combined with medical photoprotection was associated with earlier and greater improvements than oral retinol alone or standard photoprotection recommendations. These findings support further controlled studies to confirm efficacy and clarify the contribution of each intervention.  \nTrial Registration: Trial registration number ISRCTN42565762, retrospectively registered on 18 May 2026.  \nKeywords: Actinic keratosis; Oral retinol; Medical photoprotection; AKASI score  \nKey Summary P","cbCaii4vfSIuPAWN","https://ap.wps.com/l/cbCaii4vfSIuPAWN","pdf",1420389,14,"English","# Abstract\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the primary endpoint of the study?\",\"answer\":\"The primary endpoint was the change in the Actinic Keratosis Area and Severity Index (AKASI).\"},{\"question\":\"How were the patients assigned to treatment groups?\",\"answer\":\"Patients were randomized to oral retinol 50,000 IU/day (group A), oral retinol plus medical photoprotection (group B), or standard photoprotection recommendations (group C).\"},{\"question\":\"What did the results show about oral retinol combined with photoprotection?\",\"answer\":\"Oral retinol combined with medical photoprotection produced earlier and greater improvements than oral retinol alone or standard photoprotection, with significant reductions observed across multiple time points in group B.\"}]","Oral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis - A Randomized, Open-Label, Prospective, Multicentric Study | PDF",1790123870,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7a8edc6aed0540cdbcf9fe1084b1ec9.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2c769d5f18f6cbc53ce5151d5e233a8.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfdf62d69a19c1c8e9574dc3486bf124.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91cd6edeee0602bf6e7a2c6608fd722a.webp",980,1301]